Pembrolizumab Clinical Trial
Official title:
Pembrolizumab for Adjuvant Treatment After R0 Resection of Thoracic ESCC Patients With Lymph Node Positive: A Single-arm, Open-label, PhaseⅡTrial
The purpose of this study is to observe and evaluate the efficacy and safety of postoperative adjuvant treatment of pembrolizumab in patients with thoracic esophageal squamous cell carcinoma (ESCC) who have not received neoadjuvant therapy before undergoing R0 resection, and have positive postoperative lymph nodes.
For patients with thoracic esophageal squamous cell carcinoma (ESCC) who have undergone R0 resection, have not received neoadjuvant therapy, and have positive postoperative lymph nodes, there is no international consensus on whether postoperative adjuvant therapy is required. The JCOG9204 study reported that for patients with ESCC with positive lymph nodes after R0 resection, postoperative adjuvant chemotherapy can improve the disease-free survival (DFS) of the ESCC patients. However, due to the adverse effects of chemotherapy, patients are often difficult to tolerate. We designed a single-arm, open-label, phase II trial of pembrolizumab for adjuvant treatment after R0 resection of thoracic ESCC Patients with lymph node positive. The purpose of this study is to observe and evaluate the efficacy and safety. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06389422 -
Phase II Study of Moderate-dose Hypofractionated RT Combined With Pembrolizumab for HCC With Diffuse Tumor Thrombosis
|
Phase 2 | |
Recruiting |
NCT06102395 -
Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC
|
Phase 3 | |
Recruiting |
NCT05910710 -
Impact of Immuno-Oncologic Agent on Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
|
||
Not yet recruiting |
NCT05286320 -
Phase Ib/II Trial of Combining Pembrolizumab and Lenvatinib With SBRT for HCC Patients With Portal Vein Thrombosis.
|
Phase 1/Phase 2 | |
Recruiting |
NCT04955743 -
Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma
|
Phase 2 | |
Terminated |
NCT04925986 -
Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC
|
Phase 2 | |
Not yet recruiting |
NCT04333004 -
Analysis of Gut Microbiota in Patients With Brain Metastasis of Non-small Cell Lung Cancer Treated by Pembrolizumab Combined With Chemotherapy
|
Phase 1/Phase 2 | |
Recruiting |
NCT04393883 -
A Study With Pembrolizumab for Non-small Cell Lung Cancer (NSCLC)
|
N/A | |
Recruiting |
NCT04813523 -
Pembrolizumab Plus Neoadjuvant Chemotherapy for Locally Advanced EGJ Adenocarcinoma
|
Phase 2 |